Form 4: Krystal Biotech Director, Daniel Janney, Awarded Stock Options

Director Daniel Janney of Krystal Biotech, Inc. was granted stock options to purchase 5,000 shares of common stock on June 30, 2024.

Summary

• Daniel Janney, a director of Krystal Biotech, Inc., was awarded stock options on June 30, 2024.
• The options grant the right to buy 5,000 shares of Krystal Biotech's common stock at an exercise price of $183.64 per share.
• The options vest in equal monthly installments over a one-year period.
• The options expire on June 30, 2034.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a stock option grant. It's a standard practice, so the sentiment is moderately positive as it suggests continued alignment of interests.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and contribution to the company's success.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors in publicly traded biotech companies.
• The vesting schedule of one year is relatively standard.
• The specific number of shares and exercise price would be benchmarked against similar companies based on market capitalization and stage of development.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the director.
• Employees may see it as a sign of confidence in the company's future.

Key Dates